Betta Pharmaceuticals said its pan‑RAS inhibitor BPI‑572270 capsule completed
first‑participant dosing in an Australia Phase I/II study today. Preclinical
data show strong inhibition in tumor cells and xenograft models with diverse RAS
mutations (KRAS, NRAS, HRAS, including G12X, G13X, Q61X) across pancreatic,
non-small-cell lung and colorectal cancers, and report favorable
pharmacokinetics and safety.
